Mani Foroohar
Stock Analyst at Leerink Partners
(1.37)
# 3,166
Out of 4,670 analysts
180
Total ratings
38.78%
Success rate
-16.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $46 → $44 | $14.11 | +211.84% | 10 | Nov 19, 2024 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $20 → $19 | $6.47 | +193.66% | 2 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $20.30 | +254.68% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $5.41 | +214.23% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $44.73 | +9.55% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $23.42 | +96.41% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $14.27 | +54.17% | 6 | Oct 16, 2024 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Outperform | $40 → $36 | $7.79 | +362.13% | 8 | Sep 19, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $9 → $8 | $5.70 | +40.35% | 7 | Sep 3, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $34.01 | +82.30% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.49 | +23.93% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $20.84 | +39.16% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $114.23 | +101.35% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $2.66 | +50.38% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.59 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.68 | +303.65% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $0.55 | +81.85% | 10 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.38 | +194.12% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $18.54 | +115.75% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $41.11 | +126.22% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $14.30 | +487.41% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.44 | +186.89% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $9 → $8 | $0.35 | +2,185.06% | 10 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $25.05 | +207.39% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $244.89 | -41.61% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.98 | +0.33% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $47.88 | +58.73% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.02 | +1,583.17% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $6.04 | +231.13% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Outperform
Price Target: $46 → $44
Current: $14.11
Upside: +211.84%
Lexeo Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $20 → $19
Current: $6.47
Upside: +193.66%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.30
Upside: +254.68%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $5.41
Upside: +214.23%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $44.73
Upside: +9.55%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $23.42
Upside: +96.41%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $14.27
Upside: +54.17%
4D Molecular Therapeutics
Sep 19, 2024
Reiterates: Outperform
Price Target: $40 → $36
Current: $7.79
Upside: +362.13%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Market Perform
Price Target: $9 → $8
Current: $5.70
Upside: +40.35%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $34.01
Upside: +82.30%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.49
Upside: +23.93%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $20.84
Upside: +39.16%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $114.23
Upside: +101.35%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $2.66
Upside: +50.38%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $9.59
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.68
Upside: +303.65%
Dec 22, 2023
Downgrades: Market Perform
Price Target: $1
Current: $0.55
Upside: +81.85%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $2.38
Upside: +194.12%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $18.54
Upside: +115.75%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $41.11
Upside: +126.22%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $14.30
Upside: +487.41%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.44
Upside: +186.89%
Jan 23, 2023
Maintains: Market Perform
Price Target: $9 → $8
Current: $0.35
Upside: +2,185.06%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $25.05
Upside: +207.39%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $244.89
Upside: -41.61%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.98
Upside: +0.33%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $47.88
Upside: +58.73%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.02
Upside: +1,583.17%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $6.04
Upside: +231.13%